2-乳腺癌新辅助治疗临床思路幻灯片.pptxVIP

乳腺癌新辅助治疗临床思路;Neoadjuvant of treatment for breast cancer;The first generation of neoadjuvant clinical trials - NSABP 18 ;The second generation of neoadjuvant clinical trials-NSABP 27;NSABP-B18/27Neoadjuvant vs adjuvant “AC”;Question;Part Ⅰ:Proposal for the standard characterisation of the population to treat;Subtypes by IHC -ASCO/CAP guidelines;Shanghai Breast Cancer Survival Study datas;;Subtypes;Subtypes;All patients 6377;OS analysis by pCR;ClinicalTrial.gov网站显示全球目前正在进行中的总共有15项乳腺癌新辅助化疗的III期临床试验 其中有7项是基于分子分型的试验，受试对象为三阴性乳腺癌或HER2阳性乳腺癌 未进行分子分型的试验8项，其中5项新药试验，3项寻求验证新的分子标志物的指导意义的试验，1项研究双膦酸盐疗效的试验 已经没有正在进行中的非基于分子分型的标准化疗的乳腺癌新辅助化疗临床试验;Part Ⅱ: Proposal for Use of the functional and molecular imagine as endpoint?;Part Ⅱ: Proposal for Use of the functional and molecular imagine as endpoint?;; Characteristics of patients;Primary result- For all cases AUC;The SUV decrease rate and tumor response;ROC curves of different subtypes;Part Ⅱ: Proposal for Use of the functional and molecular imagine as endpoint?In our study-conclusions;Part Ⅲ :Proposal for the standard evaluation of the response to treatment 1, PCR;Part Ⅲ :Evaluation of the response to treatment1, PCR;III期、随机、对照试验，新辅助治疗 样本量：512 主要研究终点：pCR率;;Part Ⅲ :Evaluation of the response to treatment2, Ki-67;Part Ⅲ :Evaluation of the response to treatment3 , Preoperative Endocrine Prognostic Index(PEPI);Part Ⅲ :Standard evaluation of the response to the treatmentconclusion;Part Ⅳ:Standard definition of survival endpoint?- is lacking;Systemic treatment pCR vs long-term outcomes in neoadjuvant ;Future perspectives and conclusions; Thank you!